Avacta Group Plc · LSE:AVCT
Avacta — H1 2023 Earnings Presentation
33 slides from Avacta's earnings presentation, Sep 28, 2023
Slide 1: Avacta Group plc Interim Results
Avacta Group plc Interim Results for the Period Ending June 30th, 2023 28th September, 2023
Slide 2: Disclaimer
Disclaimer No representation or warranty, expressed or implied, is made or given by or on behalf of Avacta Group plc (the “Company” and, together with its subsidiaries and subsidiary undertakings, the “Group”) or any of its directors or any other person as to the accuracy, completeness or fairness o
Slide 3: Avacta Group plc
Avacta Group plc Our purpose is to improve patients’ lives and grow shareholder value by developing novel cancer therapies and powerful diagnostics using our proprietary Affimer® and pre|CISION™ platforms. Therapeutics Diagnostics Harnessing our proprietary technologies M&A led strategy to build an
Slide 4: Investment Highlights
Investment Highlights • A UK-based life sciences company focused on improving healthcare outcomes and generating shareholder value through targeted cancer treatments and diagnostics. • Therapeutics division is harnessing proprietary Affimer® and pre|CISIONTM platforms to develop novel cancer therapi
Slide 5: Avacta Group plc Interim Results
Avacta Group plc Interim Results for the Period Ending June 30th, 2023 5
Slide 6: Interim Results for the Six Months Ending 30th June 2023
Interim Results for the Six Months Ending 30th June 2023 Income (£m) 30th June 2023 30th June 2022 31st Dec 2022 Statement Revenue 11.89 5.52 9.65 Gross profit 6.75 5.27 7.24 Research/Manufacturing costs (6.01) (6.00) (11.10) S, G & A costs (8.65) (4.69) (11.23) Adjusted EBITDA (7.91) (5.42) (15.09)
Slide 7: Interim Results: Segment Analysis
Interim Results for the Six Months Ending 30th June 2023 Operating (£m) 30 June 2023 30 June 2022 Segment Dx Tx Central Total Dx Tx Central Total Analysis Revenue 9.90 1.99 - 11.89 0.08 5.44 - 5.52 Gross profit 4.76 1.99 - 6.75 0.03 5.24 - 5.27 Research/Manufacturing (0.66) (5.35) - (6.01) (1.13) (4
Slide 8: Interim Results: Cash Flow
Interim Results for the Six Months Ending 30th June 2023 Cash Flow (£m) 30th June 2023 30th June 2022 31st Dec 2022 Cash at 1 January 41.78 26.19 26.19 Operating cash outflows (8.05) (9.63) (16.43) Investing activities (7.35) 0.09 (25.04) Financing activities (0.56) 0.37 56.90 Other 0.15 - 0.16 Cash
Slide 9: Interim Results: Balance Sheet
Interim Results for the Six Months Ending 30th June 2023 Balance (£m) 30th June 2023 30th June 2022 31st Dec 2022 Sheet Non-current assets 46.98 17.94 37.10 Current assets (exc. cash/deposits) 14.80 10.50 13.77 Cash/deposits 25.97 17.02 41.78 Current liabilities (12.54) (5.51) (9.78) Non-current lia
Slide 10: Avacta Therapeutics Business Update
Avacta Therapeutics Business Update 10
Slide 11: Targeting Payloads Directly to the Tumour
Targeting Payloads Directly to the Tumour Reducing systemic toxicities of chemotherapies and improving tolerability for patients through tumour-specific activation Common Doxorubicin Toxicities The Problem Alopecia pre|CISIONTM • Chemotherapy, cytotoxic agents • Targets the tumour tissue and and imm
Slide 12: FAPa and the pre|CISION Platform
FAPa and the pre|CISIONTM Platform Targeting the tumour microenvironment through fibroblast activation protein alpha • pre|CISIONTM is a highly specific substrate FAP Concentration in a Range of Solid Tumours Global Incidence for fibroblast activation protein-a (FAPa), an extracellular enzyme that i
Slide 13: The pre|CISION Platform
The pre|CISIONTM Platform pre|CISIONTM: a four-component platform to build a pipeline of tumour targeted anti-cancer drugs FAP-substrate Active agent Capping group Optional spacer and/or peptide (as required) Modulate/optimise Selectivity for tumour Cleavage kinetics Cell killing payload pharmacokin
Slide 14: AVA6000: Targeting Doxorubicin to the Tumour
AVA6000: Targeting Doxorubicin to the Tumour Reducing systemic toxicities of chemotherapies and improving tolerability for patients through tumour-specific activation Unlocking of active chemotherapy in tumour by FAP Released pre|CISION Doxorubicin AVA6000 chemistry is excreted FAP = Patient adminis
Slide 15: AVA6000: Ongoing Phase 1 Dose Escalation Trial
AVA6000: Ongoing Phase 1 Dose Escalation Trial Phase 1a Dose Escalation AVA6000 Dose Regimen - 3 weekly cycles Multiple of equivalent (Doxorubicin Equivalent Dose) Primary Objectives standard doxorubicin • Safety and tolerability of AVA6000. dose level (approx.) • Maximum tolerated dose and/or recom
Slide 16: Summary of ALS-6000-101 Phase 1 Dose Escalation Data
Summary of ALS-6000-101 Phase 1 Dose Escalation Data Excellent safety profile, biopsies confirm release of doxorubicin in the tumour tissue at therapeutic levels and confirmed clinical signs of activity • 35 patients with a range of solid tumours dosed across six dose escalation cohorts. • Currently
Slide 17: AVA6000: Clinical and Regulatory Strategy
AVA6000: Clinical and Regulatory Strategy Clinical development in soft tissue sarcoma (Phase 1 to 2) Development Rationale in Soft Tissue Sarcoma (STS) • Advanced, metastatic soft tissue sarcoma (STS) • Doxorubicin is the only therapy indicated for first-line monotherapy in advanced STS • Limited cu
Slide 18: pre|CISION Pipeline: AVA3996
pre|CISION Pipeline: AVA3996 AVA3996 is a FAP-activated proteasome inhibitor with potential for use in solid tumour indications • The “proteasome” is the cell’s “garbage disposal” system that breaks down protein waste. AVA2727D • A working proteasomal degradation pathway (“garbage disposal”) is esse
Slide 19: In-vivo Efficacy in Multiple Tumour Models
In-vivo Efficacy in Multiple Tumour Models AVA3996 is as effective as Velcade in several PDX models of cancer without showing the same toxicities Melonoma PDX Model • AVA3996 is as effective as Velcade • Mice did not show the same • Velcade dose had to be reduced (bortezomib) in the melanoma toxicit
Slide 20: Affimer Next-generation Biotherapeutics
Affimer® Next-generation Biotherapeutics What is an Affimer®? Technical Benefits Differentiated Biotherapies Based on a naturally occurring human Smaller (14 kD), simpler and more robust, Flexible solutions for difficult-to-drug protein (stefin A) and engineered to soluble and more stable than antib
Slide 21: Affimer Internal Research Programmes
Affimer® Internal Research Programmes AVA028 PDL1/Cytokine Multi-specific AVA021 Multispecific Immunotherapy Tumour Microenvironment Activated Drug Conjugates • Bispecific Affimer/ immunoctyokines utilise • AVA021 is an Affimer® bispecific including over-expression of PD-L1 on tumour cells to • Cyto
Slide 22: AffyXell – Joint Venture in the Cell & Gene Therapy
AffyXell – Joint Venture in the Cell & Gene Therapy A joint venture in South Korea with Daewoong Pharmaceutical to develop engineered mesenchymal stem cells that express and secrete immuno-modulatory Affimer molecules to treat autoimmune diseases Next-generation Stem Cell Therapies • Renewable “off-
Slide 23: LG Chem – Multi-target Partnership
LG Chem – Multi-target Partnership A multi-target development partnership and licensing deal worth up to $310 million with a focus on oncology and inflammatory diseases PDL1/XT Antagonist • PD1/PDL1 axis Affimer inhibitor. • Half-life extension using Affimer XT® a human serum albumin binder. • Small
Slide 24: Avacta Therapeutics Pipeline
Avacta Therapeutics Pipeline Pipeline addressing some of the hottest areas in oncology from targeted medicines to multispecifics + © Avacta Group plc 2023 (CONFIDENTIAL) 24
Slide 25: Avacta Diagnostics Business Update
Avacta Diagnostics Business Update 25
Slide 26: Avacta Diagnostics: M&A Led Growth Strategy
Avacta Diagnostics: M&A Led Growth Strategy VISION MISSION Build a full spectrum, Innovate to make market differentiated European in- leading diagnostic vitro diagnostics (IVD) business solutions available to all, supporting healthcare to inform treatment and professionals and broadening monitor hea
Slide 27: A Full Spectrum IVD Business
A Full Spectrum IVD Business Supporting healthcare professionals ………. and broadening access to diagnostics Centralised Testing Decentralised Testing Pathology Laboratory Rapid PoC Tests Self-sampling Diagnostics Value Chain Research Product Manufacturing Sales and Logistics and Development Marketing
Slide 28: Rationale for Acquisitions of Launch and Coris
Rationale for Acquisitions of Launch and Coris Supporting healthcare professionals ………. and broadening access to diagnostics Centralised Testing Decentralised Testing Pathology Laboratory Rapid PoC Tests Self-sampling Sales and Logistics and Marketing Distribution • Lead generation • Sales channel C
Slide 29: Launch Diagnostics: Growth Opportunities
Launch Diagnostics: Growth Opportunities Opportunities for growth in sales and margin through geographical expansion, cross-selling to customers gained during the pandemic and expansion of product range Investment in Sales and Portfolio Expansion Geographical Expansion Marketing • Investment in sale
Slide 30: Coris BioConcept: Growth Opportunities
Coris BioConcept: Growth Opportunities Opportunities for growth through improved distribution network and broadened product portfolio Distribution Network Product Portfolio Expansion • Improvement in the quality and • Market-led product development management of the distributor and product acquisiti
Slide 31: Differentiation in a Competitive POCT Market
Differentiation in a Competitive POCT Market Affimer® Competitive Advantages Avacta’s proprietary • High specificity and sensitivity. technology with significant • Rapidly generated. technical and commercial • No immune response required. benefits to differentiate • Flexible formatting for different
Slide 32: Summary
Summary • A UK-based life sciences company focused on improving healthcare outcomes and generating shareholder value through targeted cancer treatments and diagnostics. • Therapeutics division is harnessing proprietary Affimer® and pre|CISIONTM platforms to develop novel cancer therapies targeted to
Slide 33: www.avacta.com
www.avacta.com